证券记录 · 已归档季度
EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
18被追踪持有人
—Δ持有人
60.09M持有股份
$5.55B报告持仓市值
+0新建仓位
−0清仓
所有持股数据:仅限已追踪的 13F 管理人,普通股持仓,报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 165 | -6 | 426.85M | $38.52B | +2 | −7 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | — | — |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | — | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | — |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | — | 60.09M | $5.55B | — | — |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 9 | Wellington Management ✦ | 16.92M | — | $1.56B | 0.3% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (被动) | 13.24M | — | $1.22B | 0.1% | n/c | 1 | SEC ↗ |
| 11 | Geode Capital Management ✦ (被动) | 13.24M | — | $1.22B | 0.1% | n/c | 1 | SEC ↗ |
| 12 | Norges Bank ✦ (被动) | 8.54M | — | $788.63M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 8.27M | — | $764.05M | 0.3% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 7.34M | — | $677.60M | 0.1% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 7.34M | — | $677.60M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 1.81M | — | $167.28M | 0.1% | n/c | 1 | SEC ↗ |
| 17 | Adage Capital Partners ✦ | 649.66K | — | $60.01M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Citadel Advisors ✦ | 624.40K | — | $57.68M | 0.1% | n/c | 1 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 624.40K | — | $57.68M | 0.1% | n/c | 1 | SEC ↗ |
| 20 | Millennium Management ✦ | 524.21K | — | $48.42M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 519.81K | — | $48.02M | 0.3% | n/c | 1 | SEC ↗ |
| 22 | Point72 Asset Management ✦ | 444.16K | — | $41.03M | 0.1% | n/c | 1 | SEC ↗ |
| 23 | Baillie Gifford ✦ | 352.30K | — | $32.54M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | Baillie Gifford ✦ | 352.30K | — | $32.54M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | Baillie Gifford ✦ | 352.30K | — | $32.54M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Baillie Gifford ✦ | 352.30K | — | $32.54M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 309.12K | — | $28.55M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 309.12K | — | $28.55M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 309.12K | — | $28.55M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 309.12K | — | $28.55M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Arrowstreet Capital ✦ | 225.02K | — | $20.79M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Two Sigma Investments ✦ | 152.01K | — | $14.04M | 0.0% | n/c | 1 | SEC ↗ |
| 33 | D. E. Shaw & Co. ✦ | 89.65K | — | $8.28M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | D. E. Shaw & Co. ✦ | 89.65K | — | $8.28M | 0.0% | n/c | 1 | SEC ↗ |
| 35 | Marshall Wace ✦ | 74.67K | — | $6.90M | 0.0% | n/c | 1 | SEC ↗ |
| 36 | Gotham Asset Management ✦ | 11.86K | — | $1.10M | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构(SEC结构化数据, Q1 2026): 4 持有人, 229.24K 股份, $319,498 已申报. 这是与上方被追踪全域数据不同的较早期间,两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数,而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 11
Lippis Daniel J.
Officer · 619 股 · $56,967
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓(被追踪范围,变动对比集);内部人行为来自Form 3/4/5;重大持股来自Schedule 13D/13G;所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据